MI
SONN

MMCAP International’s Sonnet BioTherapeutics SONN Stock Holding History

MMCAP International’s Portfolio SONN Stock Details SONN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-133,590
Closed -$166K – 176
2025
Q2 		$166K Hold
133,590
– – 0.02% 87
2025
Q1 		$179K Buy
+133,590
New +$205K 0.03% 57

Other funds holding SONN

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BC
BIT Capital Berlin, Germany $3.38B AUM 214.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MMCAP International's SONN Position: Q3 2025 in Review

MMCAP International sold out of Sonnet BioTherapeutics (SONN) in Q3 2025, closing a stake of 133,590 shares — an estimated $166K sold.

MMCAP International first reported a position in SONN in Q1 2025 and held it in 2 quarters. The position peaked at $179K in Q1 2025. 27 funds tracked by Wall St. Rank hold SONN as of Q3 2025.

  • MMCAP International reported no remaining Sonnet BioTherapeutics position as of Q3 2025 after selling out during the quarter.
  • MMCAP International sold 133,590 Sonnet BioTherapeutics shares in Q3 2025, an estimated $166K.
  • MMCAP International first reported a position in Sonnet BioTherapeutics in Q1 2025 and held it in 2 quarters.
  • MMCAP International's Sonnet BioTherapeutics position peaked at $179K in Q1 2025.
  • 27 funds tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q3 2025.

Based on MMCAP International's 13F filing for Q3 2025, filed 10 Nov 2025.